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orbidity and Mortality After Cardiac Transplantation
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haled M. Ziada, MD,† Timothy D. Crowe, BS,* Jingyuan Feng, MS,‡ William A. Magyar, BS,*
obert E. Hobbs, MD, FACC,* Randall C. Starling, MD, FACC,* James B. Young, MD, FACC,*
atrick McCarthy, MD, FACC,§ Steven E. Nissen, MD, FACC*
leveland, Ohio; Lexington, Kentucky; and Chicago, Illinois
OBJECTIVES The aim of this study was to determine whether angiographically silent early coronary intimal
thickening could predict long-term morbidity and mortality.
BACKGROUND Although intravascular ultrasound (IVUS) is widely used to detect early transplant coronary
disease, its prognostic significance has not been well defined.
METHODS The study cohort consisted of 143 patients who underwent early multivessel (2.1  0.7
arteries/patient) IVUS examination 1.0  0.5 month and 12.0  1.0 month after
transplantation. The change in intimal thickness was evaluated using paired analysis of 1,069
matched sites. Rapidly progressive vasculopathy was defined as the change in intimal
thickness0.5 mm. Patients were followed for a primary end point of all-cause mortality and
a secondary composite end point of mortality and nonfatal myocardial infarction (MI).
Angiographic disease, defined as any 50% diameter stenosis, was assessed in 126 patients.
RESULTS Intravascular ultrasound at one year demonstrated rapid progression in 54 (37%) of 143
patients and new lesions in 67 (47%) of 143 of patients. At a mean clinical follow-up of 5.9
years, more patients with rapidly progressive vasculopathy died, as compared with those
without (26% vs. 11%, p  0.03). Death and MI also occurred more frequently among those
with rapid progression than in those without it (51% vs. 16%, p  0.0001). There was no
significant difference in outcome in patients with and without donor-transmitted lesions.
Angiographic disease was found in 11 (22%) of 50 patients with and in 2 (2.1%) of 76 patients
without (p  0.003) rapidly progressive vasculopathy. The IVUS-defined rapid progression
correlated highly with future development of angiographic disease (p  0.0005).
CONCLUSIONS Rapidly progressive vasculopathy by IVUS, defined as an increase of 0.5 mm in intimal
thickness within the first year after transplantation, is a powerful predictor of all-cause
mortality, MI, and angiographic abnormalities. Accordingly, such patients may be candidates
for more aggressive anti-atherosclerotic and/or immunosuppressive therapy. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.12.076Cardiol 2005;45:1538–42) © 2005 by the American College of Cardiology Foundation
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song-term success after heart transplantation is primarily
imited by the development of coronary vasculopathy, the
ajor cause of death beyond the first post-transplant year
1,2). Early transplant coronary artery disease (CAD) is
linically silent, and ischemia is usually not evident until the
isease is far advanced (3–7). Often, the first symptoms are
udden death, serious arrhythmias, or heart failure. Tradi-
ionally, annual surveillance coronary angiography has been
mployed to detect allograft vasculopathy in the early stages,
ut this approach is limited because early atherosclerosis
ends to be undetectable by angiography (8).
Intravascular ultrasound (IVUS) has been proposed as a
ore sensitive method than angiography to detect and
uantify early transplant coronary disease (8–11). A few
From the *Department of Cardiovascular Medicine, Cleveland Clinic Foundation,
leveland, Ohio; †Gill Heart Institute, University of Kentucky, Lexington, Kentucky;
Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation,
leveland, Ohio; and §Division of Cardiothoracic Surgery, Northwestern University,
chool of Medicine, Chicago, Illinois.b
Manuscript received September 2, 2004; revised manuscript received November 21,
004, accepted December 10, 2004.ross-sectional studies have correlated ultrasound findings
ith subsequent clinical events, but did not have serial
maging data (12–16). Therefore, we performed systematic
VUS imaging at two time points—shortly after transplan-
ation and one year later—with the goal of determining
hether angiographically silent early coronary intimal thick-
ning could predict long-term morbidity and mortality.
ETHODS
atient population. The study population consisted of 363
atients who underwent orthotopic heart transplantation
etween December 1992 and January 1998. Of these, 143
ad baseline and one-year paired IVUS studies. Patients
ho survived one year after transplantation were included in
he study. Ineligibility for cardiac catheterization, refusal of
he patient to participate in the study, and presence of
ngiographic stenoses too severe to permit safe IVUS
maging were the most common reasons for exclusion. The
tudy protocol was approved by the institutional review
oard, and patients signed an informed consent form.
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May 3, 2005:1538–42 IVUS Findings Predicts Post-Transplant OutcomeVUS. The method of imaging has been reported in detail
17,18). After diagnostic coronary angiography, patients
ere given intravenous heparin and intracoronary nitroglyc-
rin. A 30-MHz, 3.5-F monorail ultrasound catheter (Bos-
on Scientific, Watertown, Massachusetts) connected to a
edicated scanner (Hewlett-Packard, Andover, Massachu-
etts) was advanced over an angioplasty guidewire. The
ost distal transducer location was documented by angiog-
aphy, followed by a slow, steady, manual pullback from
istal to proximal, with continuous recording on videotape
hile ultrasound landmarks were identified using voice
nnotation. An attempt was made to image all three
oronary arteries.
VUS analysis. Technicians in the IVUS core laboratory,
ho were blinded to clinical data, reviewed the baseline and
ollow-up image acquisition sequences to accurately match
he coronary segments using the landmarks. They digitized
ull-motion ultrasound sequences (30 frames/s) into a 640
480 pixel matrix with 24 bits per pixel.
For each Coronary Artery Surgery Study (CASS) seg-
ent, the site of maximal intimal thickness was identified
rom the one-year study (19). These same sites were then
dentified on the baseline IVUS study to yield a pair of
easurements. The maximal change in intimal thickness
ithin each segment (one year minus baseline) was calcu-
ated for each patient.
efinitions. A “donor lesion” was defined as a site with a
aximum intimal thickness 0.5 mm at the baseline
xamination. A de novo lesion was defined as maximum
ntimal thickness 0.5 mm on follow-up examination at a
ite where intimal thickness was 0.5 mm on the baseline
tudy. Rapidly progressive transplant vasculopathy was de-
ned as the presence of at least one site with an increase of
0.5 mm in maximum intimal thickness from baseline to
ne-year measurement (Fig. 1). Clinically significant angio-
raphic disease was defined as any new lesion 50% in
everity by quantitative coronary angiography.
linical events. The study’s clinical end points were pro-
pectively defined. The primary end point was all-cause
ortality. The secondary end point was a composite of
eath and nonfatal myocardial infarction (MI). Myocardial
nfarction was defined by new abnormal Q waves or a new
egmental wall motion abnormality at catheterization or
chocardiography. Double counting of death and MI was
voided. Rejection was defined as cellular rejection grade3A
ased on International Society for Heart and Lung Transplan-
Abbreviations and Acronyms
CAD  coronary artery disease
CMV  cytomegalovirus
IVUS  intravascular ultrasound
MI  myocardial infarctionation criteria by an experienced cardiac pathologist. lngiographic follow-up. Most recent and one-year post-
ransplant angiograms were analyzed using computerized
lectronic calipers (Philips Inturis Suite, version 2.2, Philips
edical Systems, N.A., Bothell, Washington) or manual
lectronic calipers (Mitutoyo Corp., Kawasaki, Japan). Sev-
nteen cine films were not available.
tatistical analysis. Descriptive statistics were presented as
he mean value  SD for continuous variables and as
requencies and percentages for categorical variables. In the
ultivariable Cox proportional hazard model, the following
ariables were collected prospectively or obtained by chart
eview: donor disease, de novo lesions, donor age, recipient
ge, hypertension, diabetes mellitus, history of smoking,
ecipient cytomegalovirus (CMV), lipid profile at one year,
schemic time, rejection during the first year, and the use of
ydroxymethyl glutaryl-coenzyme A (HMG-CoA) reduc-
ase inhibitors. Kaplan-Meier survival and event-free sur-
ival curves were constructed for patients with and without
apidly progressive transplant vasculopathy. A p value of
0.05 was considered significant. All analyses were per-
ormed using SAS statistical software, version 8.0 (SAS
nstitute Inc., Cary, North Carolina).
ESULTS
atient population. The donor and recipient characteris-
ics of the study cohort are summarized in Table 1. Rapid
rogression occurred more commonly in recipients with
iabetes mellitus and higher triglyceride levels, as well as in
hose who were cytomegalovirus (CMV) positive. On mul-
ivariable logistic regression analysis, recipient CMV status
nd diabetes mellitus were the only independent predictors
f rapidly progressive vasculopathy.
VUS findings. In 143 patients, baseline and follow-up
VUS examinations were performed at 1.0  0.5 and 12.0
1.0 months after transplantation. Paired analysis of 1,069
atched sites was performed in 297 arteries (mean 2.1
rteries/patient). Atherosclerotic (donor) lesions were iden-
ified in 78 donor hearts (55%) at baseline examination. In
he first year after transplantation, 67 patients (47%) devel-
ped de novo lesions. Rapidly progressive transplant vascu-
igure 1. There is a 0.5 mm difference between the intimal thickness
bserved at baseline. One-year intravascular ultrasound images which
emonstrate rapidly progressive transplant vasculopathy.opathy occurred in 54 patients (37%) (Fig. 2).
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IVUS Findings Predicts Post-Transplant Outcome May 3, 2005:1538–42linical outcome. Clinical follow-up was available in all
atients for an average duration of 5.9 years (range 1.1 to 8.9
ears) after transplantation. During the follow-up period,
here were 25 deaths (17%). Fourteen (26%) of 54 patients
ith and 11 of 89 (12%) without rapidly progressive disease
ied (p  0.027) (Fig. 3). Of the 30 (21%) MIs, 21 (40%)
ere in patients with and 9 (10%) were in those without
apidly progressive vasculopathy (p  0.0001). Death or
onfatal MI occurred in 44 patients (31%); 28 (51%) in
atients with and 16 (18%) in those without rapidly pro-
ressive disease (p  0.0001). Overall survival and MI-free
urvival at a mean of 5.9 years of follow-up was significantly
horter in patients with rapidly progressive vasculopathy
Fig. 3). When patients were classified based on one-year
ltrasound finding of de novo lesions, those with new
esions had a significantly shorter event-free survival, al-
hough overall survival was similar (Fig. 4).
evelopment of angiographic disease. Significant angio-
raphic disease was observed in three patients (2.1%) at 1
Table 1. Differences in the Patients With and
Vasculopathy
Characteristic
All Pati
(n  1
Donor age (yrs) 33 
Recipient age (yrs) 52 
Recipient gender (male, %) 81
Hypertension (%) 16
Smoking history (%) 73
Diabetes (%) 14
Baseline creatinine (mg/dl) 1.4 
Recipient CMV (% positive) 61
History of ischemic cardiomyopathy (%) 54
Ischemic time (min) 141 
BMI (kg/m2)—1 yr 32.0 
Lipid profile—1 yr
Total cholesterol (mg/dl) 230 
LDL-cholesterol (mg/dl) 146 
HDL-cholesterol (mg/dl) 46 
Triglycerides (mg/dl) 200 
Statins use at 1 yr (%) 34
Episodes of 3A rejection at 1 yr (%) 55
*Between patients with and without rapidly progressive vasc
BMI  body mass index; CMV  cytomegalovirus; HDigure 2. Distribution of patients according intravascular ultrasound
ndings.
F
pear and 13 patients (10.3%) at a mean follow-up of 5.1
ears (range 2.1 to 8.9 years). Of these 13 patients, 11 had
VUS-defined rapidly progressive vasculopathy, and 2 did
ot (p  0.003). Although a higher percentage of patients
ith de novo lesions by IVUS at one year eventually
eveloped angiographic disease, this difference was not
tatistically significant. Rapidly progressive vasculopathy at
ne-year ultrasound was strongly correlated with future
evelopment of angiographic disease (chi-square test for
orrelation, p  0.0005). The sensitivity and specificity of
apidly progressive vasculopathy for predicting future angio-
raphic disease were 84% and 64%, respectively.
redictors of death and MI. On univariate analysis, the
nly significant predictors of all-cause mortality were rapidly
rogressive transplant vasculopathy and donor age. The only
ignificant predictors of the composite end point of death
nd nonfatal MI were rapidly progressive vasculopathy,
resence of de novo lesions at one-year IVUS, and donor
ge. Of the 143 patients in our cohort, 22 patients were
hought to have humoral and cellular rejection, and 3
out Rapidly Progressive Transplant
Rapidly Progressive Vasculopathy
p Value*
Present
(n  54)
Absent
(n  89)
35  13 31  12 NS
54  9 50  11 NS
80 83 NS
17 16 NS
76 71 NS
23 9 0.01
1.4  0.6 1.4  0.5 NS
69 48 0.03
57 52 NS
139  52 143  44 NS
34  10.0 30.7  7.2 NS
233  58 228  60 NS
144  44 147  53 NS
43  14 47  13 NS
239  129 175  87 0.002
43 29 NS
59 52 NS
hy.
igh-density lipoprotein; LDL  low-density lipoprotein.With
ents
43)
13
11
0.5
47
8.5
59
50
14
110igure 3. Distribution of events in patients with and without rapid
rogression of transplant vasculopathy. MI  myocardial infarction.
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May 3, 2005:1538–42 IVUS Findings Predicts Post-Transplant Outcomeatients had only humoral rejection without cellular rejec-
ion. There was no significant correlation between grade 3A
ejection and clinical outcomes in our study. In our cohort of
43 patients, there were 73 cases of donor CMV, 101 cases
f recipient CMV, and 65 cases of CMV mismatch. There
as no correlation between clinical end points and CMV
tatus or CMV prophylaxis.
The presence of donor lesions was not predictive of
dverse outcomes, whereas development of de novo lesions
ignificantly predicted the composite end point of death or
onfatal MI, but not all-cause mortality. In a multivariate
ox proportional hazards model, the presence of rapidly
rogressive transplant vasculopathy was the only indepen-
ent predictor of all-cause mortality (hazard ratio [HR]
.36, 95% confidence interval [CI] 1.1 to 5.2; p  0.034)
nd the composite end point of death or nonfatal MI (HR
.26, 95% CI 1.7 to 6.2; p  0.0003).
ISCUSSION
his study provides strong evidence supporting our hypoth-
ses that the development of transplant vasculopathy in the
rst year after transplantation predicts all-cause mortality,
onfatal MI, and the subsequent development of angio-
raphic coronary obstructions. These data demonstrate the
bility of IVUS to identify a high-risk population in the first
ear after transplantation and underscore the importance of
erial ultrasound examinations.
Previously published reports suggested an association
etween ultrasound findings and clinical outcomes. In four
ross-sectional studies, patients with severe intimal thick-
ess (defined differently as 0.3 mm, 0.5 mm, or 1
m) at a single IVUS examination, one to five years after
ransplantation, had more subsequent cardiac events (12–
5). However, none of these studies employed a multi-
essel, serial ultrasound examination early after transplanta-
ion, limiting their value in establishing the relationship
etween the development of vasculopathy and subsequent
vents.
Compared with available cross-sectional studies, system-
tic imaging early and one year after transplantation elimi-
ates the confounding effects of differing time intervals
etween transplantation and ultrasound examination and
igure 4. Kaplan-Meier all-cause mortality (left) and death and myocar-
ial infarction (MI) (right) rates of patients with and without rapidly
rogressive transplant vasculopathy. Thick lines  without rapid progres-
ion; thin lines  with rapid progression.llows accurate assessment of donor-transmitted atheroscle- 4osis and allograft vasculopathy (17). In previous studies,
nly the most proximal segments of a single coronary artery
ere analyzed. We have previously shown that such an
pproach can lead to underdiagnosis of transplant vascu-
opathy, and thus we advocate multivessel imaging (20).
The present study examines the impact of IVUS findings,
ndependent of other confounding variables, including re-
ection episodes, age, gender, and other atherosclerosis risk
actors. Early identification of a high-risk patient population
an help to focus intensive preventive measures to curtail
ransplant vasculopathy. The lipid profile was significantly
ifferent in patients with and without rapid progression,
aising a possibility that better control of lipids may retard
he progression of vasculopathy lesions and improve out-
omes (21). Our data provide a rationale for including IVUS
nd points in clinical trials examining the effects of various
herapeutic interventions, including new immunosuppres-
ive and anti-atherosclerotic agents in transplant recipients
22). In this study, the presence of donor-transmitted
isease detected by ultrasound was not associated with a
orse clinical outcome. The data on the influence of donor
ge on the outcomes of heart transplantation are controver-
ial (23–25).
Interestingly, there were nine patients who did not have
vidence of rapidly progressive vasculopathy who developed
I on an average of 2.3 years after the IVUS examination.
otential explanations for this finding include undetected
picardial lesions secondary to sampling error, distal small
essel disease, and possibly plaque rupture.
tudy limitations. There are certain limitations of our
tudy. Selection bias may have excluded patients who might
ave influenced our findings. During the time period of this
tudy, less than half of the patients were treated with statins,
n intervention now known to inhibit transplant CAD
21,27). We did not measure the total plaque burden in the
oronary arteries but performed manual pullback and used
he most diseased site as the representative of total plaque
urden. Finally, MI, which is included in the secondary end
oint, may be difficult to diagnose in heart transplant
atients.
onclusions. This study demonstrates that rapid progres-
ion of intimal thickening in the first year after transplan-
ation predicts all cause-mortality, MI, and the subsequent
evelopment of angiographically severe CAD. Accordingly,
uch patients may be candidates for more aggressive anti-
therosclerotic and/or immunosuppressive therapies. Ther-
pies that reduce development of rapidly progressive allo-
raft vasculopathy in the first year after transplantation
ould potentially yield significant improvements in long-
erm prognosis.
eprint requests and correspondence: Dr. E. Murat Tuzcu,
epartment of Cardiovascular Medicine, Desk F-25, The Cleve-
and Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio
4195. E-mail: tuzcue@ccf.org.
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